Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most distribution/availability and substitution claims are absent from the provided FDA label text. Only the general statement that Xarelto is a prescription medicine is weakly/indirectly supported; no safety-relevant label content was included to verify alignment.
Category Scores
Accurate Statements
Xarelto is a prescription medicine.
Partially supported only indirectly by Medication Guide context; the provided evidence does not explicitly state this phrase.
Unsupported Statements
Xarelto is typically available through major retail pharmacies that fill prescriptions.
No support in the provided label sections/text.
Availability of Xarelto depends on location, the strength needed, and what the pharmacy stocks.
No support in the provided label sections/text.
Many insurers' pharmacy plans offer mail-order delivery for maintenance medicines like Xarelto.
No support in the provided label sections/text.
With a mail-order option, the prescriber usually sends the prescription to the plan's mail-order pharmacy or pharmacy network.
No support in the provided label sections/text.
In some cases, pharmacies may dispense a generic version of rivaroxaban instead of the brand name Xarelto.
No support in the provided label sections/text.
Generic substitution depends on local rules and the prescription instructions, such as if the prescription says 'dispense as written,' and on coverage.
No support in the provided label sections/text.
Contradictions
Important Omissions
No alignment-relevant safety-critical label elements (contraindications, boxed warnings, warnings/precautions, dosing safety) were addressed in the evaluated response claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
While the specific claims focus on distribution/substitution and are largely unsupported by the provided label text (not directly safety-critical), the response provides no safety-critical label alignment (contraindications/boxed warnings/dosing/warnings).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Most claims are absent from the provided FDA label text; distribution/mail-order/generic substitution operational details are not supported.
Suggested Improvement
Limit claims to label-supported information; avoid asserting pharmacy/insurer/mail-order/substitution practices unless directly supported by the prescribing information. Include safety-critical labeling elements only when relevant and supported by the provided label sections.